Role of the Immune Environment in Response to Therapy in Breast Cancer
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer
- Sponsor
- Abramson Cancer Center at Penn Medicine
- Enrollment
- 300
- Locations
- 1
- Primary Endpoint
- Collecting, processing and archiving breast cancer tumor tissues
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.
Investigators
Jennifer Zhang
Assistant Professor of Surgery
Abramson Cancer Center at Penn Medicine
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Collecting, processing and archiving breast cancer tumor tissues
Time Frame: Through study completion, average of 2 years
This study will collect and analyze tumor samples from women diagnosed with primary breast cancer. The investigators will dissociate fresh tumor samples and analyze single cell suspensions by flow cytometry. Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between breast cancer subtypes (HR+HER2-, HER2+, triple negative). Percentage of dendritic cell and T cell subsets and dendritic cell and T cell activation markers will be compared between HR+HER2- untreated breast cancers compared to HR+HER2- chemotherapy treated breast cancers.
Secondary Outcomes
- Associating breast cancer dendritic cell infiltrate with outcome(5 years)